The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAccording to reports, Alcon Inc. reported sales of $2.7 billion for the first quarter of 2026, marking a 10% increase year-over-year. Alongside the revenue growth, the company announced a new $1.5 billion share repurchase program to return capital to shareholders. However, Barclays reduced its price target for ALC shares to $78 from $90 while maintaining an Equal Weight rating on the stock.
Alcon's performance was bolstered by robust demand for dry eye treatments and successful new product launches, maintaining its competitive edge against industry peers. Compared to the previous quarter, the company demonstrated steady organic growth momentum. Per market data, the adjustment by Barclays highlights a broader analyst trend of recalibrating valuation multiples in the medical device sector despite strong underlying operational beats.
Traders should watch ALC price levels, which stood at $84.20 (close May 14, 2026), to see if the buyback support outweighs the impact of the target price cut. Looking ahead, upcoming inflation data including the German CPI on May 12, 2026, may influence broader sector sentiment. The execution speed of the $1.5 billion buyback remains a key catalyst for the stock's technical support in the near term.